Phase III, Placebo-controlled, Randomized, Double-blind, Multicenter, Parallel-group comparative study to Evaluate the Efficacy and Safety of Patient Initiated Therapy of ASP2151 in Patients with Recurrent Herpes Labialis

开始日期2019-09-25

申办/合作机构

Maruho Co., Ltd.

JPRN-jRCT2080224870 / Completed临床3期

开始日期2019-09-25

申办/合作机构

Maruho Co., Ltd.

100 项与阿莫奈韦相关的临床结果

登录后查看更多信息

100 项与阿莫奈韦相关的转化医学

登录后查看更多信息

100 项与阿莫奈韦相关的专利（医药）

登录后查看更多信息

项与阿莫奈韦相关的文献（医药）

2024-10-02·Expert Opinion on Therapeutic Patents

Helicase–primase inhibitors for the treatment of herpes simplex virus infections – patent evaluation of WO2023/225162 from Gilead Sciences Inc

Review

作者: Kleymann, Gerald ; Gege, Christian

Helicase-primase is an interesting target for small-molecule therapy of herpes simplex virus (HSV) infections. With amenamevir already approved for varicella-zoster virus and herpes simplex in Japan and with pritelivir's granted breakthrough therapy designation for the treatment of acyclovir-resistant HSV infections in immunocompromised patients, the target has sparked interest in helicase-primase inhibitors (HPIs). Here, we analyze the first patent application from Gilead in this field, which pursued a me-too approach combining elements from an old Bayer together with a recent Medshine HPI application (which covers the Phaeno Therapeutics drug candidate HN0037). The asset was contributed to Assembly Biosciences, where it is under development as ABI-1179 at the investigational new drug (IND) enabling stage for high-recurrence genital herpes. A structure proposal for indolinoyl derivative ABI-1179 is presented, showing its potential opportunities and limitations compared to other HPIs.

2024-10-01·The Journal of Dermatology

An exploratory study of the efficacy and safety of amenamevir for the treatment of herpes zoster in patients receiving immunosuppressive drugs

Article

作者: Yasumoto, Shinichiro ; Fukuda, Hiroaki ; Oka, Daigo ; Arakawa, Masataka ; Takeuchi, Satoshi ; Sasaki, Ryo ; Shirahama, Shigeho ; Imafuku, Shinichi ; Urabe, Kazunori ; Ono, Fumitake ; Yamamoto, Takenobu

AbstractAmenamevir is an oral once‐daily antiherpesvirus drug that can be administered without dose adjustment in patients with impaired renal function. There are currently no clinical data on immunocompromised patients with herpes zoster treated with amenamevir. Therefore, an exploratory study of the efficacy and safety of amenamevir against herpes zoster in patients with immunosuppression was conducted. Inclusion criteria included patients with acute herpes zoster receiving immunosuppressive drugs or those with malignant tumors or autoimmune diseases. Twenty‐four patients were included and received amenamevir (400 mg once daily after meals) for up to 14 days. The primary end point of overall improvement in skin symptoms 7 days after treatment initiation (day 7) was 58.3% for “markedly improved” and 20.8% for “improved.” The combined improvement rate was 79.2% (95% confidence interval, 57.8–92.9), and 20.8% of patients experienced “worsened” symptoms. The secondary end points of overall improvement in skin symptoms on day 14 and day 28 were 95.7% and 100%, respectively. The skin symptoms progressed during treatment, peaking on day 7, and then began to heal. By Kaplan–Meier estimation, the median periods to complete crusting and healing were both day 14. There were five adverse events with a possible causal relationship to amenamevir (bacterial skin infection, anemia, hyponatremia, headache, and abnormal liver function) in one of the 24 patients. Although the bacterial skin infection was severe, all events in this patient were reported to be either recovered or recovering. These findings indicate that amenamevir can be effective and safe in immunocompromised patients with herpes zoster. However, as worsening can happen around day 7, it is necessary to carefully monitor such patients and switch to other therapies such as intravenous acyclovir if necessary.Clinical trial identifier: Japan Registry of Clinical Trials jRCTs031190208.

2024-09-01·Journal of Infection and Chemotherapy

Disproportionality analysis of amenamevir-induced encephalopathy using the Japanese adverse drug event report database

Article

作者: Ashida, Akira ; Ogawa, Taku ; Nishihara, Masami ; Yamada, Tomoyuki ; Kusaka, Yusuke ; Tanaka, Tomoko

INTRODUCTIONAnti-herpesvirus drug-induced encephalopathy can complicate herpes zoster treatment; however, the association between the recently developed anti-herpesvirus drug amenamevir and encephalopathy development remains unknown. Determining the characteristics of amenamevir-induced encephalopathy is essential for potentially improving patient outcomes in the treatment of herpes zoster. The aim of this study is to identify the association between amenamevir treatment and encephalopathy and to determine the risk factors for amenamevir-induced encephalopathy via disproportionality analysis using the Japanese Adverse Drug Event Report (JADER) database.METHODWe conducted a retrospective observational study using anonymized data from the JADER database. Encephalopathy was defined according to the Standardized Medical Dictionary for Regulatory Activities Queries specific to "Noninfectious encephalopathy/delirium." Disproportionality analysis was used to calculate the reporting odds ratios (RORs) and 95 % confidence intervals (CIs) to assess associations between amenamevir and encephalopathy. Multivariable logistic regression considered age, gender, chronic kidney disease, and cytochrome P450 3A inhibitor use as potential risk factors.RESULTSOut of 713,316 patients, 246 were prescribed amenamevir. The median onset of encephalopathy in these patients was 3 days. Disproportionality of encephalopathy was observed in patients treated with amenamevir (ROR, 3.44; 95 % CI, 2.48-4.78). Furthermore, multivariable logistic regression analysis suggested that an age of ≥70 years was associated with amenamevir-induced encephalopathy (ROR, 7.63; 95 % CI, 2.25-25.9).CONCLUSIONThese results suggest that amenamevir treatment may be associated with encephalopathy, particularly in patients aged ≥70 years. Healthcare providers should be aware of this potential risk, especially in elderly patients, to prevent severe central nervous system complications.

项与阿莫奈韦相关的新闻（医药）

2024-06-05

·maruho.co.jp

Maruho and Hyphens Pharma Announce Exclusive License Agreement for Anti-herpes Virus Agent (INN: Amenamevir) in 10 ASEAN Countries

Osaka (Japan), June 5, 2024 - Maruho Co., Ltd. ("Maruho", Head Office: Osaka, Japan, President and CEO: Atsushi Sugita) and Hyphens Pharma Pte. Ltd., a subsidiary of Hyphens Pharma International Limited ("Hyphens", Head Office: Singapore, Chairman, Executive Director and CEO: Lim See Wah) announced that the two companies have entered into a license agreement under which Maruho will license to Hyphens the rights to develop and commercialize the anti-herpes virus agent amenamevir (JNN/INN), manufactured and marketed in Japan by Maruho, hereinafter referred to as "the product", in 10 ASEAN (Association of Southeast Asian Nations)*1 countries. Under the terms of the agreement, Maruho grants Hyphens an exclusive license to develop and market the product in 10 ASEAN countries. Hyphens will proceed with the development activities necessary to bring the product to market. After the product is commercialized, Hyphens will pay royalties to Maruho based on commercialization milestones. The product exhibits high antiviral activity against the varicella-zoster virus and the herpes simplex virus by inhibiting the activity of the helicase-primase complex, which is essential for viral DNA replication. In 2012, Maruho and Astellas Pharma Inc. executed a license agreement for the development and commercialization of the product. Maruho proceeded with development in Japan and the product was approved for the indications of "herpes zoster" in 2017 and "recurrent herpes simplex" in 2023. The product is currently manufactured and commercialized under the brand name of "Amenalief® Tablets 200 mg" in Japan. In its 5th Medium-Term Plan, initiated in October 2023, Maruho introduced a new business strategy termed the "Asia Dermatology Hub Concept." Maruho established a local subsidiary in China*2 in February 2024 and is promoting business development in Asian countries and regions. This agreement is an effort to realize business development in Asia and to respond to the unmet needs of patients in ASEAN countries who have limited options for herpes treatment. Maruho and Hyphens, which both specialize in dermatology, will work to bring smiles to the faces of patients suffering from viral skin diseases such as herpes zoster and herpes simplex in the countries and regions covered by this agreement. Note The information contained in this news release in regard to pharmaceutical and developmental products is not intended for the purpose of promotion, advertising or medical advice. (*1) Thailand, Indonesia, Malaysia, Philippines, Singapore, Vietnam, Brunei, Cambodia, Myanmar, Laos (*2) Establishment of a local subsidiary in China (February 2024) https://www.maruho.co.jp/english/information/20240222.html [References] Maruho Launches Anti-Herpes Virus Agent "Amenalief Tab. 200mg" in Japan (2017/09/02) https://www.maruho.co.jp/english/information/2017090702.html Maruho Receives Manufacturing and Marketing Approval for a Partial Change of the Indication and Dosage/Administration for Anti-herpes Virus Agent "Amenalief Tab. 200mg" for the Treatment of Recurrent Herpes Simplex in Japan (2023/02/24) https://www.maruho.co.jp/english/information/20230224.html About HyphensHyphens Pharma International Limited and its subsidiaries (the "Group") is Singapore's leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia, and the Philippines, and is supplemented by a marketing and distribution network covering 14 other markets. The Group's core business comprises Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart & Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets, and sells its own proprietary range of dermatological and health supplement products. For more information, please visit https://www.hyphensgroup.com/ About MaruhoMaruho Co., Ltd. has its head office in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,566 employees (as of the end of September 2023), and net sales were approximately 85.71 billion yen in its fiscal year ended September 30, 2023. With the mission "More smiles, brighter life for you.", Maruho aims to help realize a society where everyone can live with a smile. For more information, please visit www.maruho.co.jp/english/ Contact Information: Maruho Co., Ltd. Public Relations Group, Corporate Planning Dept. Tel：+81-(0)6-6371-8831 Fax：+81-(0)6-6371-8679 Email：kouhou@mii.maruho.co.jp

引进/卖出上市批准

2023-02-24

·maruho.co.jp

Maruho Receives Manufacturing and Marketing Approval for a Partial Change of the Indication and Dosage/Administration for Anti-herpes Virus Agent "Amenalief Tab. 200mg" for the Treatment of Recurrent Herpes Simplex in Japan

Osaka (Japan), February 24, 2023 - Maruho Co., Ltd. ("Maruho", Head Office: Osaka, Japan,President and CEO: Atsushi Sugita) announces that it has received manufacturing and marketing approval from the Ministry of Health, Labor and Welfare for a partial change of the indication and dosage/administration for anti-herpes virus agent "Amenalief® Tab. 200mg" (JAN/INN: amenamevir; hereinafter referred to as "the product") for the treatment of recurrent herpes simplex in Japan. Herpes simplex is a general term for infectious diseases caused by the herpes simplex virus that infects the skin and mucous membranes (lips, eyes, genitals, etc.). Common types include labial herpes and genital herpes. Recurrent herpes simplex is a disease that develops when the herpes simplex virus that has been latently infected in the ganglia after a primary infection, is reactivated by stimuli such as stress or a weakened immune system. Additionally, it is characterized by repeated recurrence of symptoms, and many patients experience discomfort such as itching and tingling before skin symptoms such as erythema (redness), papules and blisters develop. The partial change of the indication and dosage/administration approval received today is recognized as "Patient Initiated Treatment" (PIT) for patients with recurrent herpes simplex when they become aware of the initial symptoms.1) Early treatment is possible by taking the prescribed 1200mg of this drug once after meals within 6 hours after the appearance of the initial symptoms of recurrent herpes simplex. It is hoped that this drug will be more convenient for patients since only one dose is required. Maruho, specializing in dermatology, will strive to further contribute to patients and medical professionals by providing new options for the treatment of recurrent herpes simplex. Note The information contained in this news release in regard to pharmaceutical and developmental products is not intended for the purpose of promotion, advertising or medical advice. Product Profile Brand Name Amenalief® Tab. 200mg JAN/INN Amenamevir Formulation/Dose Film coated tablets containing 200mg of amenamevir in 1 tablet Indication (Additional content is underlined) Herpes Zoster Recurrent Herpes Simplex Dosage and Administration (Additional content is underlined) (Herpes Zoster) General administration for adults is 400mg of amenamevir once a day administered orally after a meal. (Recurrent Herpes Simplex) General administration for adults is 1200mg of amenamevir administered orally after a meal. References １） Shinichiro Yasumoto, Patient-initiated-treatment (PIT) in the management of patients with recurrent herpes simplex, Japanese Journal of Clinical Dermatology, 74 (5), 135 (2020) About Amenalief Tab.Amenalief Tab. is an oral anti-herpes virus agent with a novel mechanism of action containing the non-nucleic acid analog amenamevir, created in Japan by Astellas Pharma Inc. By inhibiting the activity of the helicase-primase complex, an essential enzyme for DNA replication of the herpesvirus, it exhibits antiviral activity by suppressing double-stranded DNA cleavage and RNA primer synthesis. Maruho manufactures and commercializes the product in Japan and it has been used for the treatment of herpes zoster since 2017. Maruho's initiatives for disease caused by herpesMaruho is working to help patients suffering from herpes labialis and genital herpes to understand the diseases correctly and take appropriate measures in the event of a recurrence. Through the comprehensive herpes information site "What's herpes?" the causes and remedies for cold sores and genital herpes are explained. (https://www.maruho.co.jp/kanja/herpes/） (As Maruho markets treatments for customers in Japan, the information is only provided in Japanese). About MaruhoMaruho Co., Ltd. has its head office in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,547 employees (as of the end of September 2022), and net sales were approximately 85.67 billion yen in its fiscal year ended September 30, 2022. Pursuing its long-term corporate vision of "Excellence in Dermatology," Maruho is striving to improve the health and quality of life of people all over the world. For more information, please visit https://www.maruho.co.jp/english/ Contact Information: Maruho Co., Ltd. Corporate Communications Dept. Tel：+81-(0)6-6371-8831 Fax：+81-(0)6-6371-8679 e-mail：kouhou@mii.maruho.co.jp

上市批准临床研究

2021-01-21

·BioSpace

Chemo Drug Potentially More Potent than Remdesivir Against Coronavirus

Researchers with Shenzhen Institutes of Advanced Technology in China used a variety of computational techniques to simulate drug-virus interactions. They then screened 1,906 existing drugs to evaluate which ones might inhibit replication of SARS-CoV-2, the virus that causes COVID-19. From this broad screening, they identified four drugs that had potential to prevent replication of the virus, which they then tested in laboratory experiments. Two of the drugs, pralatrexate, a chemotherapy, and azithromycin, an antibiotic, were successful at preventing replication of the virus. More lab experiments demonstrated that pralatrexate had stronger viral inhibition than Gilead Sciences’ remdesivir, which is currently the only approved drug for COVID-19. They published their research in the journal PLOS Computational Biology. Pralatrexate is marketed by Acrotech Biopharma under the trade name Folotyn. It is indicated for relapsed or refractory peripheral T-cell lymphoma. Like many chemotherapeutics, it comes with a wide range of serious side effects, including low blood cell counts—platelets, white blood cells, and red blood cells—mucositis, which is inflamed mucous membranes, severe skin reactions, tumor lysis syndrome (TLS), increased risk of serious reactions in kidney patients, fever, dehydration, nausea, as well as significant risk for pregnant and nursing women. As a result, the authors note that immediate use of the drug for COVID-19 patients is not guaranteed, but believe their approach was useful in identifying drugs that can be repurposed. “We have demonstrated the value of our novel hybrid approach that combines deep-learning technologies with more traditional simulations of molecular dynamics,” said Haiping Zhang, study author. The research team is working to develop more computational methods for creating novel molecular structures that could be developed into new drugs to treat COVID-19. The screening method focused on viral RNA-dependent RNA polymerase (RdRp), a promising therapeutic target. The authors write that other computational drug screening methods are based on molecular docking, deep learning or Molecular Dynamics. Most of these typically depend upon a single technique or lack experimental validation. “Each computation method,” they write, “with its underlying philosophy, often has its own strong and weak points, while a proper combination and modification of such methods could provide a better solution. Previously, we have developed two deep learning-based models to estimate protein-ligand interactions: DFCNN and DeepBindBC. DFCNN uses molecular vector data of protein pocket and ligand, instead of spatial information at interaction site, to estimate the protein-ligand pair as binding or non-binding with a probability value between 0 and 1. DeepBindBc estimates the binding possibility from atom contact information at interaction surface of a modelled 3D protein-ligand complex. The input of DeepBindBC contains spatial information of the protein-ligand interface, thus it strongly complements DFCNN.” Their hybrid screening procedure was made up of DFCNN, DeepBindBC, Autodoc Vina, pocket localized molecular dynamics simulation, metadynamics, and their own inhouse-developed tools. They screened potential drugs from the TargetMol-Approved_Drug_Library, which contains 1,906 currently marketed drugs. One of the findings, less focused on COVID-19, but of particular interest to validation of the screening approach, was that DFCNN, DeepBindBC and Autodock Vina predicted different drug compounds as top hits. For example, amenamevir and azithromycin had better scores on Autodock Vina, while odanacatib and nitisinone had higher DFCNN scores. Azithromycin, with hydroxychloroquine, an anti-malarial, had demonstrated efficacy in treating COVID-19 earlier in the pandemic, but subsequent studies have failed to show that either drug is effective in treating COVID-19. For that matter, a large World Health Organization (WHO) study failed to prove remdesivir’s effectiveness in hospitalized patients, resulting in the organization issuing a conditional recommendation against its use.

100 项与阿莫奈韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10564	阿莫奈韦	J05AX26	DB11701

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
单纯疱疹	日本	Maruho Co., Ltd.	2023-02-24
带状疱疹	日本	Maruho Co., Ltd.	2017-07-03

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
单纯疱疹	临床前	英国	Maruho Europe Ltd.	2014-09-01
带状疱疹	临床前	日本	Astellas Pharma, Inc.	2007-11-13
生殖器疱疹	临床前	美国	Astellas Pharma, Inc.	2007-06-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01959295 (CTgov)	临床3期	单纯疱疹	468	ASP2151 (ASP2151)	網衊鏇壓膚築餘範壓選(膚構構網蓋選鹹夢構壓) = 衊齋簾範廠醖範遞衊餘壓遞憲蓋壓餘糧顧鏇糧 (蓋築淵齋選憲艱廠繭鏇, 蓋顧衊製簾鬱觸鏇鬱鏇 ~ 願衊憲遞繭鹹製範窪鏇) 更多	-	2024-10-09
				ASP2151 placebo (ASP2151 Placebo)	網衊鏇壓膚築餘範壓選(膚構構網蓋選鹹夢構壓) = 膚衊鹽齋廠膚簾蓋遞糧壓遞憲蓋壓餘糧顧鏇糧 (蓋築淵齋選憲艱廠繭鏇, 襯廠範簾遞顧憲鬱憲願 ~ 鹹淵壓窪觸鹽齋膚鏇網) 更多
NCT02209324 (CTgov)	临床3期	单纯疱疹	275	ASP2151	夢製遞窪壓糧遞蓋憲鬱(鹹構壓壓艱簾選簾糧廠) = 衊廠膚齋廠網鹽選網廠選遞糧顧餘襯願願範鏇 (襯窪醖鹹獵衊憲鹹蓋醖, 襯積憲艱淵鏇醖繭膚鑰 ~ 餘醖糧選餘壓鑰蓋襯積) 更多	-	2024-09-27
NCT02321748 (CTgov)	临床1期	-	24	Montelukast+ASP2151 (Montelukast)	窪憲膚鬱範衊窪鏇廠糧(壓遞憲鹹鏇襯壓蓋簾襯) = 糧衊醖範膚艱鑰鏇艱襯齋網鑰齋鹹夢簾網艱衊 (獵窪鹹廠鹽壓餘觸艱艱, 網鬱壓窪糧簾糧鹽糧餘 ~ 遞獵選顧鏇顧淵醖醖鏇) 更多	-	2019-01-14
				Montelukast+ASP2151 (ASP2151)	窪憲膚鬱範衊窪鏇廠糧(壓遞憲鹹鏇襯壓蓋簾襯) = 願糧鹽構糧夢襯鹽顧鬱齋網鑰齋鹹夢簾網艱衊 (獵窪鹹廠鹽壓餘觸艱艱, 繭顧夢顧憲廠顧製選選 ~ 築糧簾襯顧積簾鏇壓簾) 更多
NCT01959841 (CTgov)	临床3期	带状疱疹	751	ASP2151 (ASP2151(200 mg))	繭獵範觸醖願襯鏇窪襯(獵遞廠築蓋顧餘糧選廠) = 簾築鹽淵鹽鏇蓋遞獵鹽網築鏇範窪糧鬱觸鏇廠 (鬱窪構獵積齋築憲範鏇, 淵膚齋觸範遞憲願觸齋 ~ 壓觸淵廠壓衊築廠糧網) 更多	-	2018-10-18
				ASP2151 (ASP2151(400mg))	繭獵範觸醖願襯鏇窪襯(獵遞廠築蓋顧餘糧選廠) = 網窪築膚憲製糧獵鑰觸網築鏇範窪糧鬱觸鏇廠 (鬱窪構獵積齋築憲範鏇, 淵觸遞餘簾醖構遞蓋繭 ~ 艱製廠鬱鏇憲淵鹹範觸) 更多
NCT00486200 (Pubmed \| Am J Trop Med Hyg)	临床2期	生殖器疱疹	695	ASP2151 100 mg	窪積鬱網願觸衊廠網壓(繭鹽廠顧積範製網獵夢) = 餘憲壓鬱襯衊膚餘膚獵鏇鏇蓋鏇築壓餘齋餘構 (築鹽願壓繭衊淵齋淵遞 )	-	2012-04-01
				ASP2151 200 mg	窪積鬱網願觸衊廠網壓(繭鹽廠顧積範製網獵夢) = 選艱蓋築憲夢艱範製蓋鏇鏇蓋鏇築壓餘齋餘構 (築鹽願壓繭衊淵齋淵遞 )